Cerewint is under clinical development by Regeneration Biomedical and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cerewint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cerewint (RB-ADSC) is under development for the treatment of Alzheimer's disease (AD). The therapeutic candidate comprises of autologous adipose-derived stem cells (ADSCs). It is administered through intracerebroventricular route.
Regeneration Biomedical overview
Regeneration Biomedical leverages stem cell therapy development and clinical application with focus on Alzheimer’s Disease, ALS, multiple sclerosis, Parkinson’s disease and its variants, stroke, and traumatic brain injury (including chronic traumatic encephalopathy (CTE).
For a complete picture of Cerewint’s drug-specific PTSR and LoA scores, buy the report here.